- Home
- BPRN vs PBYI Comparison
BPRN vs PBYI Comparison
Compare BPRN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPRN | PBYI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BPRN | PBYI |
|---|---|---|
| Price | $34.00 | $6.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $35.00 | $7.00 |
| AVG Volume (30 Days) | 11.2K | ★ 388.1K |
| Earning Date | 01-27-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ 62.30 | 59.87 |
| EPS | ★ 2.57 | 0.74 |
| Revenue | $76,577,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $6.01 | N/A |
| P/E Ratio | $13.25 | ★ $8.18 |
| Revenue Growth | ★ 13.94 | N/A |
| 52 Week Low | $27.25 | $2.58 |
| 52 Week High | $36.95 | $6.27 |
Technical Indicators
Market Signals| Indicator | BPRN | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 60.41 |
| Support Level | $33.70 | $5.64 |
| Resistance Level | $36.70 | $6.27 |
| Average True Range (ATR) | 0.81 | 0.24 |
| MACD | -0.30 | -0.01 |
| Stochastic Oscillator | 9.23 | 67.72 |
Price Performance
Historical ComparisonAbout BPRN Princeton Bancorp Inc. (PA)
Princeton Bancorp Inc is a banking company. It is a full-service financial institution that provides business and personal banking. Its personal banking and business banking services include checking accounts and savings accounts. It offers traditional retail banking services, one-to-four-family residential mortgage loans, multi-family and commercial mortgage loans, construction loans, commercial business loans, and consumer loans, including home equity loans and lines of credit. The Bank also has two retail branches and conducts loan origination activities in select areas of the New York City metropolitan area.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.